Home
FGEN
FGEN News

Latest FibroGen Inc (FGEN) News on July 26, 2024

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

Simply Wall St.

a month ago

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

GlobeNewswire

a month ago

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

MT Newswires

2 months ago

FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

GlobeNewswire

2 months ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

GlobeNewswire

2 months ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

2 months ago

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire

2 months ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

FibroGen First Quarter 2024 Earnings: Beats Expectations

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript

Thomson Reuters StreetEvents

3 months ago

Q1 2024 FibroGen Inc Earnings Call

MT Newswires

3 months ago

Top Premarket Gainers

FibroGen to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

FibroGen to Participate in Upcoming Investor Conferences

GuruFocus.com

3 months ago

FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...

Associated Press Finance

3 months ago

FibroGen: Q1 Earnings Snapshot

FibroGen Reports First Quarter 2024 Financial Results

GlobeNewswire

3 months ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

GlobeNewswire

3 months ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire

3 months ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Zacks

3 months ago

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Zacks

3 months ago

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

Zacks

3 months ago

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

Zacks

3 months ago

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Zacks

3 months ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Zacks

4 months ago

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Zacks

4 months ago

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

Zacks

4 months ago

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

4 months ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Zacks

4 months ago

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Zacks

4 months ago

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

4 months ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Zacks

4 months ago

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Zacks

4 months ago

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

Zacks

4 months ago

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Zacks

4 months ago

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

Zacks

4 months ago

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

GlobeNewswire

5 months ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

Zacks

5 months ago

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results

Simply Wall St.

5 months ago

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results

FibroGen Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

5 months ago

FibroGen Full Year 2023 Earnings: Misses Expectations

Thomson Reuters StreetEvents

5 months ago

Q4 2023 FibroGen Inc Earnings Call

Associated Press Finance

5 months ago

FibroGen: Q4 Earnings Snapshot

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023

GuruFocus.com

5 months ago

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023

Reuters

5 months ago

UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca

Reuters

5 months ago

FibroGen regains rights to anemia drug from AstraZeneca

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

5 months ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

GlobeNewswire

5 months ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

5 months ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

GlobeNewswire

6 months ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

/C O R R E C T I O N -- Nutex Health, Inc./

PR Newswire

6 months ago

/C O R R E C T I O N -- Nutex Health, Inc./

FibroGen, Inc. (NASDAQ:FGEN) institutional owners may be pleased with recent gains after 96% loss over the past year

Simply Wall St.

6 months ago

FibroGen, Inc. (NASDAQ:FGEN) institutional owners may be pleased with recent gains after 96% loss over the past year

SYLA Technologies Announces FY2024 Financial Guidance and Upward Revision of FY2023 Dividend Forecast

GlobeNewswire

6 months ago

SYLA Technologies Announces FY2024 Financial Guidance and Upward Revision of FY2023 Dividend Forecast

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

GlobeNewswire

6 months ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio

Zacks

6 months ago

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio

Should You Investigate Mama's Creations, Inc. (NASDAQ:MAMA) At US$4.70?

Simply Wall St.

6 months ago

Should You Investigate Mama's Creations, Inc. (NASDAQ:MAMA) At US$4.70?

Radcom (RDCM) Surges 5.4%: Is This an Indication of Further Gains?

Zacks

6 months ago

Radcom (RDCM) Surges 5.4%: Is This an Indication of Further Gains?

Cambium Networks Corporation Announces Preliminary Fourth Quarter 2023 Revenues, Reporting Date and CFO Transition

PR Newswire

6 months ago

Cambium Networks Corporation Announces Preliminary Fourth Quarter 2023 Revenues, Reporting Date and CFO Transition

Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago

Simply Wall St.

6 months ago

Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance

NewMediaWire

6 months ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance

Business Wire

6 months ago

Superior Appoints Deven Petito to its Board of Directors

Investing.com

7 months ago

Shoe retailer Genesco cuts full-year earnings forecast, shares plunge premarket

Be Wary Of Latham Group (NASDAQ:SWIM) And Its Returns On Capital

Simply Wall St.

7 months ago

Be Wary Of Latham Group (NASDAQ:SWIM) And Its Returns On Capital

Health Care Roundup: Market Talk

The Wall Street Journal

7 months ago

Health Care Roundup: Market Talk

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

Investor's Business Daily

7 months ago

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

GlobeNewswire

7 months ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Relmada Therapeutics Provides Corporate Update

PR Newswire

7 months ago

Relmada Therapeutics Provides Corporate Update

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Business Wire

7 months ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Sky Harbour Announces Incoming Chief Operating Officer, New Manufacturing Leadership, and an Update on Construction Budget at Dallas-Addison Airport

Business Wire

7 months ago

Sky Harbour Announces Incoming Chief Operating Officer, New Manufacturing Leadership, and an Update on Construction Budget at Dallas-Addison Airport

Parke Bancorp Inc's Dividend Analysis

GuruFocus.com

7 months ago

Parke Bancorp Inc's Dividend Analysis

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders

GlobeNewswire

7 months ago

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders

Innate Pharma Announces Leadership Change

Business Wire

7 months ago

Innate Pharma Announces Leadership Change

Turtle Beach’s Groundbreaking & Critically Acclaimed Designed for Xbox Stealth Ultra Wireless Controller Launches Globally

Business Wire

7 months ago

Turtle Beach’s Groundbreaking & Critically Acclaimed Designed for Xbox Stealth Ultra Wireless Controller Launches Globally

PR Newswire

7 months ago

JOHN HANCOCK CLOSED-END FUNDS ANNOUNCE RENEWAL OF SHARE REPURCHASE PLANS

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

Zacks

7 months ago

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

WESTERN COPPER AND GOLD ANNOUNCES COMPLETION OF FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO

CNW Group

7 months ago

WESTERN COPPER AND GOLD ANNOUNCES COMPLETION OF FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO

Hamilton Beach Brands Holding (NYSE:HBB) investors are sitting on a loss of 18% if they invested five years ago

Simply Wall St.

8 months ago

Hamilton Beach Brands Holding (NYSE:HBB) investors are sitting on a loss of 18% if they invested five years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

GlobeNewswire

8 months ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

Zacks

8 months ago

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

Business Wire

8 months ago

M-tron Industries, Inc. to Present at Sidoti Virtual Investor Conference December 6-7

TEAF Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023

ACCESSWIRE

8 months ago

TEAF Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023

PR Newswire

8 months ago

JOHN HANCOCK CLOSED-END FUNDS DECLARE QUARTERLY DISTRIBUTIONS

TortoiseEcofin Announces Constituent Changes Due to Corporate Action

ACCESSWIRE

8 months ago

TortoiseEcofin Announces Constituent Changes Due to Corporate Action

Renovaro BioSciences Poised to Spearhead Advancements in Battle Against Diseases

NewMediaWire

8 months ago

Renovaro BioSciences Poised to Spearhead Advancements in Battle Against Diseases

Insider Sell Alert: CFO James Tivy Sells 5,000 Shares of M-Tron Industries Inc (MPTI)

GuruFocus.com

8 months ago

Insider Sell Alert: CFO James Tivy Sells 5,000 Shares of M-Tron Industries Inc (MPTI)

Dakota Gold Corp. Announces Extension of the Option Covering Certain Surface Rights of the Homestake Mine Property with Barrick Gold Corporation to 2026

Newsfile

8 months ago

Dakota Gold Corp. Announces Extension of the Option Covering Certain Surface Rights of the Homestake Mine Property with Barrick Gold Corporation to 2026

With 60% ownership, Harvard Bioscience, Inc. (NASDAQ:HBIO) boasts of strong institutional backing

Simply Wall St.

8 months ago

With 60% ownership, Harvard Bioscience, Inc. (NASDAQ:HBIO) boasts of strong institutional backing

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Formosa

GlobeNewswire

8 months ago

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Formosa

PR Newswire

8 months ago

JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA

HIGHLIGHTS: Join CEO of Live Ventures in Fireside Chat

IPO-Edge.com

8 months ago

HIGHLIGHTS: Join CEO of Live Ventures in Fireside Chat

GlobeNewswire

8 months ago

Presidio Property Trust Announces Update of Share Repurchase Program

Investors in Penns Woods Bancorp (NASDAQ:PWOD) have unfortunately lost 7.1% over the last five years

Simply Wall St.

8 months ago

Investors in Penns Woods Bancorp (NASDAQ:PWOD) have unfortunately lost 7.1% over the last five years

Thomson Reuters StreetEvents

8 months ago

Q3 2023 Quest Resource Holding Corp Earnings Call

Quest Resource Holding Corp Reports Mixed Q3 Results Amidst Integration Challenges

GuruFocus.com

8 months ago

Quest Resource Holding Corp Reports Mixed Q3 Results Amidst Integration Challenges

GlobeNewswire

8 months ago

Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

ACCESSWIRE

8 months ago

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

Alithya Group (ALYA) Reports Break-Even Earnings for Q2

Zacks

8 months ago

Alithya Group (ALYA) Reports Break-Even Earnings for Q2

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Business Wire

8 months ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

China Automotive Systems, Inc. (NASDAQ:CAAS) Q3 2023 Earnings Call Transcript

Insider Monkey

8 months ago

China Automotive Systems, Inc. (NASDAQ:CAAS) Q3 2023 Earnings Call Transcript

Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript

Motley Fool

9 months ago

Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript

Porch Group Insurance Carrier, HOA, Receives ‘A, Exceptional’ Financial Stability Rating

Business Wire

9 months ago

Porch Group Insurance Carrier, HOA, Receives ‘A, Exceptional’ Financial Stability Rating

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

GlobeNewswire

9 months ago

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

Share on Social Networks: